Evidence map›Paper›PMID 39800833›Full record

SynthesisJournal of gastrointestinal cancer2025

Curative-Intended Management of Synchronous Esophageal and Rectal Cancer-A Systematic Literature Review.

Georg W Wurschi, Claus Schneider, Thomas Ernst, Herry Helfritzsch, Jens Nowatschin, Thomas Bitter, Martin Freesmeyer, Klaus Pietschmann, Maximilian Römer

Abstract readSystematic Review
In one paragraph

Synthesis in Journal of gastrointestinal cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Georg W WurschiDepartment of Radiotherapy and Radiation Oncology, Jena University Hospital, 07747, Jena, Germany. georg.wurschi@med.uni-jena.de.
Claus SchneiderComprehensive Cancer Center Central Germany, Campus Jena, 07747, Jena, Germany.
Thomas ErnstComprehensive Cancer Center Central Germany, Campus Jena, 07747, Jena, Germany.
Herry HelfritzschDepartment of General, Visceral and Thoracic Surgery, Thuringia-Clinic Saalfeld Georgius Agricola, 07318, Saalfeld, Germany.
Jens NowatschinDepartment of Internal Medicine, Thuringia-Clinic Saalfeld Georgius Agricola, 07318, Saalfeld, Germany.
Thomas BitterComprehensive Cancer Center Central Germany, Campus Jena, 07747, Jena, Germany.
Martin FreesmeyerComprehensive Cancer Center Central Germany, Campus Jena, 07747, Jena, Germany.
Klaus Pietschmann *Department of Radiotherapy and Radiation Oncology, Jena University Hospital, 07747, Jena, Germany.
Maximilian Römer *Department of Radiotherapy and Radiation Oncology, Jena University Hospital, 07747, Jena, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeSynchronous esophageal (EC) and rectal carcinoma (RC) is a rare and challenging condition, particularly in curative-intended treatment. Especially locally advanced tumors may not be suitable for primary resection and require individual multimodal treatment. This review examines curative-intended management of synchronous EC and RC. MATERIAL AND

methodsA systematic literature search across five electronic databases according to the PRISMA guideline was conducted. Individual patient data was analyzed, including two additional cases from our institution.

resultsWe identified 9 relevant cases from 1552 results. Additionally, two male patients (62 and 65 years old) from our institution were included. Both received 5-fluorouracil/cisplatin-based chemoradiotherapy (CRT) for EC. Sequential short-course radiation (SCRT) for RC was performed in one patient. After complete response (CR) in both tumors, no consecutive surgery was performed. He underwent resection for local recurrence of RC 11 months later and is currently considered as disease-free (30 months follow-up). The second patient underwent primary resection of RC and had early progression following resection of EC. We found that most patients had advanced EC (8/11), with the majority receiving neoadjuvant (5/11) or definitive treatment (3/11). Locally advanced RC was diagnosed in 5/11 patients, primarily treated with sequential resection. Pyrimidine-based systemic treatment was common. Four relapses and two deaths were reported, but median follow-up was 11 (range 1.5-30) months only.

conclusionThe review suggests that neoadjuvant multimodal approaches may offer curative potential for synchronous EC and RC, with individualized treatment protocols adapted from single-cancer protocols. Nevertheless, data on long-term outcome is limited.

Indexed as

Esophageal NeoplasmsNeoplasms, Multiple PrimaryRectal NeoplasmsAgedAntineoplastic Combined Chemotherapy ProtocolsChemoradiotherapyHumansMaleMiddle AgedNeoadjuvant TherapyEsophagusNeoadjuvant TreatmentRectumSynchronous Cancer

Identifiers

PMID39800833
PMCPMC11725541

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.